Holen Sie sich die Stockscreener-App
17.31
6.48%
-1.20
Handel nachbörslich:
17.14
-0.17
-0.98%
Schlusskurs vom Vortag:
$18.51
Offen:
$17.62
24-Stunden-Volumen:
906.78K
Relative Volume:
2.19
Marktkapitalisierung:
$944.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.73%
1M Leistung:
+48.97%
6M Leistung:
+52.11%
1J Leistung:
-13.32%
1-Tages-Spanne:
$16.46
$18.19
1-Wochen-Bereich:
$16.46
$19.71
52-Wochen-Spanne:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
17.31 | 971.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
How Investors May Respond To Bicara Therapeutics (BCAX) FDA Breakthrough Therapy Nod for Lead Immunotherapy - Yahoo Finance
Bicara stock gains as H.C. Wainwright reiterates Buy rating on FDA breakthrough By Investing.com - Investing.com Australia
Bicara stock gains as H.C. Wainwright reiterates Buy rating on FDA breakthrough - Investing.com UK
Will Bicara Therapeutics Inc. stock see insider buyingJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Why Bicara Therapeutics Inc. stock is considered a top pick2025 Stock Rankings & Technical Pattern Based Signals - newser.com
Can Bicara Therapeutics Inc. recover in the next quarter2025 Buyback Activity & AI Enhanced Trading Alerts - newser.com
Key facts: Merck reports $63.62B revenue; Bicara gains FDA breakthrough - TradingView
Is Bicara Therapeutics Inc. stock resilient to inflationWeekly Risk Report & Safe Capital Preservation Plans - newser.com
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - MarketScreener
Is Bicara Therapeutics Inc. stock a buy before product launchesJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Using Python tools to backtest Bicara Therapeutics Inc. strategies2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Bicara stock jumps after FDA grants breakthrough therapy status By Investing.com - Investing.com Nigeria
Bicara stock jumps after FDA grants breakthrough therapy status - Investing.com
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation - MarketScreener
Bicara Therapeutics climbs after FDA's 'breakthrough' tag for cancer therapy - TradingView
Bicara Therapeutics Inc. stock chart pattern explainedWeekly Stock Report & High Accuracy Trade Alerts - newser.com
Why Bicara Therapeutics Is Rising In Pre-market? - Nasdaq
FDA grants breakthrough therapy status to Bicara’s cancer drug - Investing.com
Bicara Therapeutics Announces Ficerafusp Alfa Granted - GlobeNewswire
How to build a custom watchlist for Bicara Therapeutics Inc.Weekly Trade Recap & Intraday High Probability Alerts - newser.com
Ivan Hyep Sells 6,415 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Insider David Raben Sells 22,000 Shares - MarketBeat
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares By Investing.com - Investing.com Australia
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 18,244 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $715,176.00 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 10,900 Shares - MarketBeat
Ivan Hyep Sells 6,514 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 5,627 Shares of Stock - MarketBeat
Risk adjusted return profile for Bicara Therapeutics Inc. analyzedJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Can Bicara Therapeutics Inc. stock resist sector downturnsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares By Investing.com - Investing.com Canada
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Bicara therapeutics president Cohlhepp sells $911k in shares By Investing.com - Investing.com UK
Day 8 of Gains Streak for Bicara Therapeutics Stock with 70% Return (vs. 4.3% YTD) [10/7/2025] - Trefis
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Statistical indicators supporting Bicara Therapeutics Inc.’s strengthGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
What drives Bicara Therapeutics Inc stock priceVWAP Trading Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Is Bicara Therapeutics Inc. stock reversal real or fakeJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Key metrics from Bicara Therapeutics Inc.’s quarterly dataQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Bicara Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Bicara Therapeutics files for mixed shelf offering of up to $400 millionSEC filing - MarketScreener
How to read the order book for Bicara Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Stifel maintains Buy on Bicara stock with $47 target - MSN
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Raben David | Chief Medical Officer |
Oct 09 '25 |
Sale |
18.45 |
22,000 |
405,900 |
35,497 |
| Hyep Ivan | Chief Financial Officer |
Oct 09 '25 |
Option Exercise |
3.79 |
6,415 |
24,312 |
151,770 |
| Hyep Ivan | Chief Financial Officer |
Oct 09 '25 |
Sale |
18.23 |
6,415 |
116,931 |
145,355 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):